PARD6B

PARD6B is a scaffold subunit of the apical PAR polarity complex (PARD6B-aPKC-CDC42-PAR3) that establishes and maintains apical-basal polarity in epithelial cells and asymmetric cell fate in development (PMID:20505164, PMID:22957302). In the preimplantation mouse embryo it localizes asymmetrically to the apical pole during compaction and is required cell-autonomously for apical aPKCzeta localization, tight junction formation, blastocyst cavitation, and CDX2 expression (PMID:15950600, PMID:20505164); in epithelial and cancer cell lines its depletion abolishes tight junction assembly and membrane aPKC localization without disrupting adherens junctions, a phenotype that depends on the complete PARD6B-aPKC-CDC42-PAR3 complex (PMID:22957302). Apical positioning of PARD6B requires CDC42 activity (PMID:26772200), and the PARD6B-CDC42 interaction is gated by PAK4-mediated phosphorylation at Ser143 (PMID:25662318). Through its interaction with aPKC/PRKCZ the complex orients the mitotic spindle and controls cell lineage in progenitor populations (PMID:28285879), and PARD6B is also required for apical (but not basolateral) endosomal recycling (PMID:28069747). Upstream, apical PARD6B localization is promoted by RHO-ROCK signaling (PMID:24997360) and the transcription factor TFAP2C (PMID:25858457), and antagonized by HIPPO effectors YAP1/WWTR1 (PMID:30526858) and by LGL1, which competes with PAR-3A within the complex (PMID:29842893). Upon apical membrane perturbation by viral or bacterial toxin binding, PARD6B and aPKC undergo rapid proteasome-dependent degradation that depletes apical endosome function and confers resistance to apical infection, a cell-autonomous host defense (PMID:35143768). PARD6B further supports epithelial proliferative and tumor-associated programs, regulating AEC2 cell-cycle progression versus transdifferentiation (PMID:40001200) and promoting cancer cell EMT, invasion, and proliferation (PMID:28652146).

1. 2005 Medium

   Established that PARD6B is asymmetrically partitioned during early development, redistributing from the spindle to the apical pole at compaction independently of cell-cell contacts, marking it as an intrinsic apical polarity determinant.

   Evidence Immunofluorescence localization and contact-disruption experiments in preimplantation mouse embryos

   PMID:15950600

   Open questions at the time

   • Does not define the molecular signal driving apical redistribution
   • Localization is correlative, not loss-of-function
2. 2010 High

   Demonstrated that PARD6B is cell-autonomously required upstream of aPKCzeta apical localization for blastocyst polarity, tight junctions, cavitation, and CDX2 expression, establishing it as a functional driver rather than a passenger of polarity.

   Evidence RNAi knockdown via zygote microinjection with chimera assays and immunofluorescence in mouse embryos

   PMID:20505164

   Open questions at the time

   • Does not resolve direct binding partners mediating aPKC recruitment
   • Does not address PARD6B function outside the embryo
3. 2012 Medium

   Showed in human epithelial cells that a complete PARD6B-aPKC-CDC42-PAR3 complex is required specifically for tight junction assembly and membrane aPKC localization, separating its role from adherens junction control.

   Evidence siRNA knockdown of PAR6B and CDC42 with TJ marker immunofluorescence in MCF7 cells

   PMID:22957302

   Open questions at the time

   • Single cell line
   • Does not establish stoichiometry or direct contacts within the complex
4. 2013 Medium

   Placed PARD6B in an apical polarity module distinct from the core PCP pathway, complementary to the Gαi3/mPins domain in hair cells.

   Evidence Immunofluorescence co-localization and Gαi3/mPins genetic deletion in mouse cochlear hair cells

   PMID:23934215

   Open questions at the time

   • Correlative localization
   • Does not test PARD6B loss-of-function in this tissue
5. 2014 Medium

   Identified RHO-ROCK signaling as an upstream input segregating apical PARD6B from basal regulators, coupling polarity to Hippo/YAP-driven lineage specification.

   Evidence Pharmacological RHO/ROCK inhibition with polarity marker immunofluorescence and LATS1/2 rescue in mouse embryos

   PMID:24997360

   Open questions at the time

   • Pharmacological inhibition lacks molecular specificity
   • Direct effector linking ROCK to PARD6B not defined
6. 2015 High

   Defined a post-translational switch: PAK4 phosphorylates PARD6B at Ser143 to block its CDC42 interaction, providing a mechanism to control PARD6B localization and binding.

   Evidence In vitro kinase assay, Ser143 mutagenesis, and Co-IP interaction assays in human bronchial epithelial cells

   PMID:25662318

   Open questions at the time

   • In vivo relevance of Ser143 phosphorylation not established
   • Does not address how phosphorylation alters apical targeting in tissue
7. 2015 Medium

   Placed TFAP2C transcriptionally upstream of PARD6B, with PARD6B re-expression rescuing polarity but only partially correcting Hippo signaling, revealing PARD6B-dependent and -independent branches.

   Evidence RNAi knockdown of TFAP2C with Pard6b mRNA rescue and Hippo readouts in mouse embryos

   PMID:25858457

   Open questions at the time

   • Does not define the PARD6B-independent Hippo branch
   • Direct transcriptional regulation of PARD6B by TFAP2C not shown
8. 2016 Medium

   Showed CDC42 activity is required for apical PARD6B positioning in vivo during organ morphogenesis, linking the GTPase to PARD6B localization beyond the embryo.

   Evidence Conditional Cdc42 knockout with PARD6B localization immunofluorescence in mouse pharyngeal endoderm

   PMID:26772200

   Open questions at the time

   • Does not separate direct CDC42-PARD6B binding from indirect polarity collapse
   • Single tissue context
9. 2017 Medium

   Expanded PARD6B function to apical membrane trafficking, showing it is selectively required for apical (not basolateral) endosomal recycling.

   Evidence RNAi screen and pulse-chase transcytosis transport assays in polarized epithelial cells

   PMID:28069747

   Open questions at the time

   • Molecular link between PARD6B and the endosomal machinery undefined
   • Does not establish whether trafficking role is separable from junction role
10. 2017 Medium

    Demonstrated that the PRKCZ-PARD6B interaction controls mitotic spindle orientation and lineage, placing the complex downstream of GATA3 in progenitor cells.

    Evidence Genetic disruption of PRKCZ-PARD6B interaction with spindle and lineage assays in mouse prostate progenitors

    PMID:28285879

    Open questions at the time

    • Does not define the spindle-anchoring effectors recruited by the complex
    • Single progenitor system
11. 2017 Medium

    Linked the PARD6B/PKCζ/PAR3 complex to suppression of EMT and invasion, with hypoxia-driven downregulation promoting cancer cell motility.

    Evidence siRNA silencing with invasion/colonization assays in vitro and in vivo in lung cancer cells

    PMID:28652146

    Open questions at the time

    • Does not isolate PARD6B-specific contribution from other complex members
    • Mechanism linking hypoxia to complex downregulation unresolved
12. 2018 Medium

    Identified HIPPO effectors YAP1/WWTR1 as repressors of apical PARD6B/aPKC localization, defining a negative feedback loop reinforcing lineage segregation.

    Evidence Genetic manipulation of YAP1/WWTR1 with localization immunofluorescence and epistasis in mouse embryos

    PMID:30526858

    Open questions at the time

    • Does not identify the direct YAP/TEAD target mediating repression
    • Mechanism of apical exclusion unclear
13. 2018 Medium

    Revealed a competition mechanism whereby LGL1 displaces PAR-3A from the aPKC-PAR-6B complex, with disease relevance to pleural fibrosis.

    Evidence Co-immunoprecipitation, siRNA, and conditional Lgl1 knockout in pleural mesothelial cells

    PMID:29842893

    Open questions at the time

    • Direct vs. indirect competition not structurally resolved
    • Single disease model
14. 2022 High

    Established a host-defense role: apical membrane perturbation triggers proteasome-dependent PARD6B/aPKC degradation that depletes apical endosome function and blocks further apical infection.

    Evidence Biochemical degradation assays, proteasome inhibition, glycosphingolipid perturbation, and apical endosome functional assays

    PMID:35143768

    Open questions at the time

    • E3 ligase targeting PARD6B not identified
    • Signal coupling lipid perturbation to degradation undefined
15. 2025 Medium

    Connected PARD6B-containing complex levels to alveolar epithelial cell fate, controlling AEC2 cell-cycle progression versus transdifferentiation.

    Evidence Co-IP/mass spectrometry, overexpression/knockdown, cell cycle analysis, and 3D spheroid assays in primary mouse AEC2s

    PMID:40001200

    Open questions at the time

    • Does not define the signaling link between complex level and cell cycle arrest
    • Mechanism of transdifferentiation downstream of PARD6B unclear
16. 2025 Low

    Proposed a pro-proliferative role in colorectal cancer via miR-34c suppression and MYC upregulation.

    Evidence In vitro/in vivo knockdown and overexpression with in silico pathway analysis and miR-34c/MYC reporter assays

    PMID:40533910

    Open questions at the time

    • miR-34c/MYC axis is primarily in silico supported with limited in vitro validation
    • Does not connect this pathway to PARD6B's polarity function

• How PARD6B's apical scaffolding, endosomal, spindle-orientation, and proteostatic functions are mechanistically integrated, and the identity of the E3 ligase and direct effectors involved, remain unresolved.
• No structural model of the PARD6B-aPKC-CDC42-PAR3 complex in the corpus
• E3 ligase mediating PARD6B degradation unidentified
• Direct effectors coupling the complex to endosomes and the spindle undefined